Skip to main content

PhaseBio Pharmaceuticals Inc

PHASDelisted Dec 21, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001169245

PhaseBio Pharmaceuticals Inc was delisted on Dec 21, 2022; its insiders filed their last Form 4 on May 19, 2023; 39 institutions reported holding it in 13F filings for Q3 2022, worth $3.90M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding PhaseBio Pharmaceuticals Inc changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of PHAS: Q2 2021 compared with Q3 2021
MeasureQ2 2021Of which not filed for Q3 2021Q3 2021Change
Holders56162+7
Shares30.5M1.61M30.8M+2.00M (+6.9%)
Value$113.3M$5.98M$95.9M−$11.4M (−10.6%)

1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (13)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to PHAS in Q3 2021
InstitutionSharesValue% of portfolio
Johnson & Johnson1,607,044$5.00M0.44%
Eversept Partners, LP300,000$933.0K0.07%
Caas Capital Management LP263,172$818.0K0.06%
Marshall Wace, LLP218,877$681.0K0.00%
OrbiMed Advisors LLC177,113$551.0K0.01%
Renaissance Technologies LLC100,566$313.0K0.00%
Jump Financial, LLC43,867$136.0K0.01%
Jacobs Levy Equity Management, Inc31,324$97.0K0.00%
HRT Financial LP28,286$87.0K0.00%
Pura Vida Investments, LLC27,944$87.0K0.01%
Acadian Asset Management LLC12,550$39.0K0.00%
XTX Topco Ltd11,215$35.0K0.01%
Federated Hermes, Inc.316$1.00K0.00%

Sold out (6)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of PHAS in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Gsa Capital Partners LLP186,031$692.0K
Tibra Equities Europe Ltd91,200$339.0K
Charles Schwab Investment Management Inc17,190$64.0K
Parametric Portfolio Associates LLC10,254$38.0K
Captrust Financial Advisors521$2.00K
New York State Common Retirement Fund106$0

Not filed for Q3 2021 yet (1)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PHAS in Q2 2021 that haven't filed for Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Johnson & Johnson Innovation - JJDC, Inc.1,607,044$5.98M